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A B S T R A C T   
Introduction: We aimed to assess associations between multimodal neuroimaging measures of cholinergic basal 
forebrain (CBF) integrity and cognition in Parkinson’s disease (PD) without dementia. 
Methods: The study included a total of 180 non-demented PD patients and 45 healthy controls, who underwent 
structural MRI acquisitions and standardized neurocognitive assessment through the PD-Cognitive Rating Scale 
(PD-CRS) within the multicentric COPPADIS-2015 study. A subset of 73 patients also had Diffusion Tensor 
Imaging (DTI) acquisitions. Volumetric and microstructural (mean diffusivity, MD) indices of CBF degeneration 
were automatically extracted using a stereotactic CBF atlas. For comparison, we also assessed multimodal indices 
of hippocampal degeneration. Associations between imaging measures and cognitive performance were assessed 
using linear models. 
Results: Compared to controls, CBF volume was not significantly reduced in PD patients as a group. However, 
across PD patients lower CBF volume was significantly associated with lower global cognition (PD-CRStotal: 
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r = 0.37, p < 0.001), and this association remained significant after controlling for several potential confounding 
variables (p = 0.004). Analysis of individual item scores showed that this association spanned executive and 
memory domains. No analogue cognition associations were observed for CBF MD. In covariate-controlled 
models, hippocampal volume was not associated with cognition in PD, but there was a significant association 
for hippocampal MD (p = 0.02). 
Conclusions: Early cognitive deficits in PD without dementia are more closely related to structural MRI measures 
of CBF degeneration than hippocampal degeneration. In our multicentric imaging acquisitions, DTI-based 
diffusion measures in the CBF were inferior to standard volumetric assessments for capturing cognition- 
relevant changes in non-demented PD.   
1. Introduction 
Although Parkinson’s disease (PD) is primarily perceived as a 
movement disorder, progressive cognitive deficits typically emerge as 
the disease progresses, eventually resulting in a characteristic PD- 
associated dementia syndrome [1]. In recent years, structural neuro-
imaging proxies of cholinergic system integrity could provide indirect in 
vivo evidence for the critical role of cholinergic degeneration in 
PD-associated cognitive decline [2]. Although the cholinergic nuclei are 
not directly visible on structural MRI contrasts, volumetric analysis of 
regions-of-interest (ROI) focussed on the cholinergic basal forebrain 
(CBF) revealed marked atrophy of this region in both PD dementia 
(PDD) and pathologically related dementia with Lewy bodies (DLB) 
[3–6]. However, CBF degeneration in the predementia phase of PD and 
its relevance for the emergence of subtle cognitive deficits is less well 
explored. A previous manual volumetry study found reduced CBF vol-
umes in PD patients with mild cognitive impairment (PD-MCI) to be 
predictive of progression to dementia [7], but others found no differ-
ences between PD-MCI and PD with normal cognition at the group level 
[4]. 
More recent studies used automated CBF morphometry techniques 
based on stereotactic mappings of the cholinergic nuclei that may pro-
vide a more comprehensive, and potentially more sensitive, in vivo 
analysis of CBF degeneration [5,8–11]. Using this approach it could be 
demonstrated that although CBF volumes were not significantly reduced 
in de novo PD patients as a group, reduced CBF volumes could be 
detected in a subset of patients [9,10]. These patients also showed a 
significantly increased risk for imminent cognitive decline, suggesting 
that cognition-relevant changes in CBF volume are already present at 
this early disease stage. 
In addition to the recent in vivo research on CBF degeneration in PD, 
previous neuroimaging studies had implicated other cognition-relevant 
brain structures in PD-related cognitive impairments, particularly the 
hippocampal memory system [12–14], and the relative contributions of 
these different neuroanatomic systems to cognitive decline in PD remain 
largely unknown. Moreover, recent multimodal MRI studies indicated 
that microstructural diffusion alterations as measured by diffusion 
tensor imaging (DTI) may be more sensitive markers of 
cognition-relevant neurodegenerative processes in PD compared to 
volumetric measurements on structural MRI [11,14,15]. 
In the present study we aimed to comprehensively assess the relation 
of MRI-measured CBF and hippocampal volumes with cognitive differ-
ences in a well-characterized multicentric cohort of non-demented PD 
patients, and to further explore the utility of DTI-based diffusion alter-




This study included a total of 180 non-demented PD patients and 45 
healthy controls from the COPPADIS-2015 (Cohort of Patients with 
Parkinson’s Disease in Spain, 2015) cohort. COPPADIS-2015 is an 
ongoing prospective, multi-center, non-interventional, long-term study 
on PD progression that includes detailed clinical evaluations as well as 
assessments of serum biomarkers, genetics, and neuroimaging data [16]. 
The participants selected for the current cross-sectional study corre-
spond to a subset of COPPADIS-2015 participants from five different 
centers who underwent a 3D T1-weighted structural MRI scan at the 
baseline evaluation. A subsample of 73 PD patients also underwent a 
baseline DTI acquisition. Patients were excluded if they met screening 
criteria for dementia (Mini Mental State Examination (MMSE) < 26 and 
inability of performing basic activities of daily living as determined by 
clinical interview). Detailed inclusion and exclusion criteria for the 
COPPADIS-2015 study have been detailed before [16] and are summa-
rized in the supplement. 
This study was approved by the local ethics committees on human 
experimentation of the different participating centers. Written informed 
consent was obtained from all subjects participating in this study. 
2.2. Clinical and neuropsychometric evaluation 
Disease stage and motor symptom severity were evaluated by the 
Hoehn and Yahr (H&Y) scale and the Unified Parkinson’s Disease Rating 
Scale-Part III (UPDRS-III), both assessed in “off” condition. 
Neuropsychological performance was evaluated in “on” condition 
using the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS) [17], 
including individual item scores for tests of sustained attention, working 
memory, alternating and action verbal fluency, immediate and delayed 
verbal memory, naming, as well as drawing and copy of a clock. 
Although all patients were non-demented according to clinical screening 
criteria, eight patients had PD-CRS total scores ≤64 indicative of 
dementia-level cognitive impairment [17] and were excluded from 
further analyses. 
2.3. MRI acquisition 
Structural MRI data were acquired on different clinical MRI scanners 
(one 1.5 T and four 3 T machines) using scanner-specific 3D T1- 
weighted structural imaging sequences with approximately 1 mm 
isotropic spatial resolution. For a subsample of the PD patients scanned 
on 3 T MRI scanners additional diffusion-weighted images were ac-
quired using scanner-specific echo-planar imaging sequences. Detailed 
center-specific acquisition parameters for the T1-and diffusion-weighted 
scans are listed in Supplementary Table 1. Average time between MRI 
acquisition and cognitive evaluation was 75 ± 67 days (IQR: 24–104 
days). 
2.4. Processing and analysis of structural MRI and DTI data 
Automated CBF and hippocampus volumetry on T1-weighted struc-
tural MRI scans followed procedures that have been described in detail 
previously [5,9,18,19], and were implemented using statistical para-
metric mapping software (SPM12, Wellcome Trust Center for Neuro-
imaging) and the CAT-toolbox (http://www.neuro.uni-jena.de/cat/) 
implemented in Matlab R2018a (MathWorks, Natick, MA, USA). Briefly, 
MRI scans were segmented into gray matter (GM), white matter, and 
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cerebrospinal fluid partitions and high-dimensionally registered to 
Montreal Neurological Institute (MNI) standard space using the highly 
accurate DARTEL algorithm [18,19]. GM volumes of the CBF and hip-
pocampus were then automatically extracted by summing up the 
modulated GM voxel values within respective ROIs in MNI standard 
space. The total intracranial volume (TIV), as a measure of head size, 
was calculated as the sum of total volumes of the GM, white matter, and 
cerebrospinal fluid partitions [19]. 
The CBF ROI was based on our previous methodological study 
characterizing functionally homogeneous subdivisions within the 
human CBF as defined by combined information from existing stereo-
tactic atlases of basal forebrain cholinergic nuclei in MNI space [20]. In 
our primary analyses we used the total anatomic CBF space as an overall 
measure of CBF degeneration, but in secondary analyses we also 
considered the functionally-defined anterior-medial (aCBF) and 
posterior-lateral (pCBF) subdivisions separately (Supplementary 
Fig. S1). The hippocampus ROI was based on a recently developed MNI 
standard space template of international consensus criteria for hippo-
campus outlines on structural MRI [18]. 
Processing of DTI data was implemented using the DTI toolbox of FSL 
(Version 5.0, FMRIB, Oxford, UK), and included correction for eddy 
current effects and head motion, skull stripping, and fitting of diffusion 
tensors to the data to derive scalar maps of mean diffusivity (MD). MD 
maps were spatially normalized to MNI standard space using the 
deformation fields derived from normalization of the co-registered T1- 
weighted MRI scans. Individual CBF and hippocampal MD indices were 
calculated by extracting average voxel values within the respective ROIs 
from the normalized MD maps [11]. 
All images passed initial visual quality assessments for gross image 
artefacts, as well as subsequent assessments of overall tissue type seg-
mentation and global spatial normalization accuracy. Mean absolute 
and relative inter-volume head displacement during the DTI acquisitions 
were 1.76 ± 2.04 mm and 0.61 ± 0.71 mm, respectively. 
2.5. Statistical analysis 
Differences in ROI volumes between groups were assessed with 
analysis of covariance (ANCOVA) models controlled for acquisition site, 
TIV, age, sex, and education. Associations of volumetric and diffusivity 
indices of CBF degeneration with cognitive deficits in PD were assessed 
using linear regression models with PD-CRS total score (PD-CRStotal) as 
the primary outcome. Separate linear regression models were calculated 
for CBF volume and CBF MD as predictor variables, and for significant 
models the added value of combining volumetric and microstructural 
information was assessed in combined multimodal regression models. 
Secondary analyses assessed the domain specificity of CBF-cognition 
associations across individual PD-CRS item scores, as well as the 
regional specificity of the cognition associations across aCBF and pCBF 
subdivisions. All regression models were controlled for acquisition site, 
and TIV in the case of volumetric measures, and the robustness of sig-
nificant CBF-cognition associations was assessed in additional models 
further controlling for several potential confounding variables, 
including age, sex, education, disease duration, motor symptom severity 
(UPDRS-III scores), total levodopa equivalent doses, and offset between 
MRI acquisition and cognitive evaluation. Analogous models were 
calculated using volumetric and diffusivity indices of hippocampal 
degeneration. In a complementary analysis we additionally assessed 
associations between neuroimaging markers and cognition separately 
for each acquisition site, followed by a meta-analysis of the center- 
specific outcomes (see supplementary material). Statistical analyses 
were performed using the computing environment R (version 3.5.1). 
Following recommendations described in the statistical literature [21], 
we primarily report uncorrected p-values in this hypothesis-driven study 
with a limited number of planned comparisons focused on the associa-
tion between neuroimaging measures of CBF degeneration and cognitive 
deficits in PD. However, for transparency we also report p-values 
corrected using the False Discovery Rate (FDR). 
Table 1 
Sample characteristics.   
HC 
(N = 45) 
PD 





Statistic value (P 
value) 
Demographics 
Sex (M/F) 30/15 113/67  X2 = 0.10 
(0.755) 






14/19/12 95/44/41  X2 = 7.78 
(0.020) 
Clinical variables 
Age at onset, years  57.6 
(10.1)   
Disease duration, 
years  




(10.1)   
Hoehn & Yahr stage  2 (2–2)   
Anticholinergic 
treatment (No/Yes)  
175/5   
Total levodopa 
equivalent doses  
517 (430)   
Cognitive characteristics 
Total MMSE 29.7 (0.5) 29.5 (0.8) 0.33 t = 2.57 (0.012) 








8.3 (1.4) 7.6 (1.9) 0.36 t = 2.57 (0.012) 
Sustained 
attention 
9.3 (0.8) 8.8 (1.6) 0.37 t = 3.15 (0.002) 
Working memory 8.4 (1.5) 8.0 (1.8) 0.26 t = 1.70 (0.093) 




5.2 (1.9) 4.9 (2.6) 0.14 t = 0.98 (0.328) 
Alternating 
verbal fluency 
12.9 (3.5) 11.8 (3.8) 0.31 t = 1.94 (0.057) 
Action verbal 
fluency 
16.4 (4.2) 15.2 (5.5) 0.22 t = 1.53 (0.129) 
Posterior-cortical items 
Naming 19.8 (0.5) 19.3 (1.6) 0.37 t = 3.75 
(<0.001) 
Clock drawing 9.8 (0.4) 9.3 (1.6) 0.38 t = 4.19 
(<0.001) 













0.003 F = 0.14 (0.71) 
The descriptive values presented are: number for categorical variables; median 
(IQR) for Hoehn & Yahr stage; and mean (standard deviation) for all other 
continuous variables. Statistic values correspond to chi-squared test for cate-
gorical variables, t-test for continuous variables, and ANCOVA models 
controlled for acquisition site, TIV, sex, age and education for regional MRI 
volumes. Disease duration was defined as the time passed since initial symptoms 
were noticed by the patient, irrespective of the time of clinical diagnosis. 
Abbreviations: HC = Healthy controls; PD = Parkinson’s disease; 
TIV = Intracranial volume; MMSE = Mini Mental State Examination; UPDRS-III 
= Unified Parkinson’s Disease Rating Scale-Part III; PD-CRS = PD-Cognitive 
Rating Scale. 
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3. Results 
3.1. Patient characteristics 
Demographic and clinical characteristics of the participants are 
detailed in Table 1. Although all PD patients were non-demented by 
inclusion criteria, they showed a large variability in global cognitive 
performance (PD-CRStotal: mean = 94 ± 13, range = 68–135). According 
to a previously established cut-off of PD-CRStotal ≤ 81 [17], 34 patients 
(19%) would classify for a categorisation as PD-MCI. 
In covariate-controlled comparisons to the healthy controls, neither 
CBF nor hippocampal volume was significantly reduced in the PD group 
as a whole (p > 0.71). 
3.2. MRI-measured cholinergic basal forebrain and hippocampus volume 
in relation to cognition in PD 
Table 2 summarizes the results of linear regression models for the 
association of CBF and hippocampus volume with PD-CRS scores. After 
accounting for TIV and acquisition site, lower CBF volume was signifi-
cantly associated with lower PD-CRStotal (rpartial = 0.37, p < 0.001), and 
this association also remained significant after controlling for con-
founding variables (p = 0.004). Among individual PD-CRS item scores, 
CBF volume was most strongly associated with immediate memory, but 
covariate-controlled models were also significant for delayed memory, 
working memory, and alternating verbal fluency. In subregion-specific 
analyses all associations were slightly more pronounced for the pCBF 
than for the aCBF, but none of the differences were statistically signifi-
cant (p > 0.83; Supplementary Table S2). 
In the basic regression models (only controlling for TIV and acqui-
sition site) hippocampal volume was also associated with PD-CRStotal 
(rpartial = 0.24, p = 0.002) and particularly with delayed and immediate 
verbal memory scores, but none of these associations remained signifi-
cant in the fully covariate-controlled model (Table 2). 
For comparison, we also assessed associations of CBF and hippo-
campus volumes with cognitive performance in the healthy control 
group using identical linear regression models. In analyses controlled for 
TIV and acquisition center, neither PD-CRS total score nor any of the 
individual item scores were significantly associated with CBF or hip-
pocampal volume in this group (p > 0.18). 
3.3. DTI-based diffusion measures of cholinergic basal forebrain and 
hippocampal integrity in relation to cognition in PD 
In the subsample with DTI data, CBF volume showed a comparable 
association with PD-CRStotal as in the full sample (Fig. 1A; Supplemen-
tary Table S3), but CBF MD was not significantly associated with PD- 
CRStotal (Fig. 1C, Table 3; rpartial = − 0.10, p = 0.42) or any individual 
item scores (Table 3). Combining both volumetric and diffusivity mea-
surements of CBF integrity into a multimodal regression model for PD- 
CRStotal did not increase the fit compared to the model based on CBF 
volume alone (ΔR2=0.003, p = 0.60). 
Associations between hippocampal volume and PD-CRS scores 
remained nonsignificant in the subsample with available DTI data 
(Fig. 1B; Supplementary Table S3), but hippocampal MD did show a 
significant association with PD-CRStotal (rpartial = − 0.43, p < 0.001; 
Fig. 1D), which also remained significant in fully covariate-controlled 
models (p = 0.02), and was mainly driven by associations with alter-
nating verbal fluency scores (Table 3). Combining volumetric and 
diffusivity measurements of hippocampus integrity into a multimodal 
regression model for PD-CRStotal did not significantly increase the fit 
compared to the model based on hippocampal MD alone (ΔR2=0.034, 
p = 0.23). 
4. Discussion 
In this study we analyzed multimodal neuroimaging measures of CBF 
degeneration in relation to cognitive performance in a well- 
characterized multicentric sample of PD patients without dementia, 
and further assessed the specificity of the CBF-cognition associations in 
relation to imaging markers of hippocampal degeneration. We found 
that lower cognitive performance among PD patients was robustly 
associated with structural MRI-based volume measures of CBF degen-
eration, but not with volumetric measures of hippocampal degeneration. 
In a subset analysis of DTI data, diffusivity measures of the CBF were not 
associated with cognition, but diffusivity measures of the hippocampus 
were more sensitive to cognition-relevant tissue changes than hippo-
campal volume. 
While severe CBF degeneration is an established neuropathologic 
feature of dementia in PD that can be readily detected on structural MRI 
Table 2 
Linear model stats for the association of volumetric imaging markers with 




Cholinergic Basal Forebrain Hippocampus 
Part. 
r 
T value (P 
value) 




PD-CRStotal 0.37 5.20 
(<0.001) 





























































































Naming 0.05 0.59 
(0.554) 
0.554 0.16 2.07 
(0.04) 




Clock copy 0.23 3.16 
(0.002) 





0.244 0.10 1.24 
(0.218) 
0.488 
Linear model stats are presented as (partial) r and T value (P value). For each 
cognitive item score, results from single predictor linear regression models 
(controlled for acquisition site and TIV) are indicated in the first row, and for 
significant models fully covariate-controlled regression results are indicated in 
the second row. 
Abbreviations: PD-CRS = PD-Cognitive Rating Scale. 
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scans, the degree to which CBF degeneration also relates to more subtle 
cognitive deficits that emerge in the predementia phase of PD is less well 
known [2–5,22]. A previous study on the de novo PD cohort of the 
Parkinson’s Progression Marker Initiative (PPMI) did not observe sig-
nificant differences in MRI-measured CBF volume between healthy 
controls and the PD group as a whole, but found reduced CBF volume in 
a subset of PD patients, and these were at a significantly higher risk for 
future cognitive decline [9]. A subsequent study further showed that 
lower CBF volume was also associated with worse cognitive perfor-
mance in non-demented PD patients at a cross-sectional level [10]. Here 
we add further evidence for a robust association between MRI-measured 
CBF volume and cognitive performance in PD without dementia by 
analysing an independent, multicentric sample of well-characterized PD 
patients and using strict control of several possible confounding 
variables. 
Analysis of the individual item scores of the PD-CRS battery revealed 
that CBF volume was associated with performance in several neuro-
psychological functions including both executive and memory domains. 
This is partly in contrast to predictions from the “dual syndrome hy-
pothesis”, which states that the cholinergic deficit in PD may be more 
closely associated with impairments in mnemonic and visuospatial 
functions, as compared to more dopamine-dependent executive dys-
functions [1]. Similar to our present findings, previous PET-based 
imaging studies of cholinergic degeneration in non-demented PD found 
that cortical cholinergic denervation was associated with reduced per-
formance in several cognitive domains, including attention, executive 
function, and memory, but not with visuospatial function [23,24]. It 
could be possible that the relative influence of CBF degeneration on 
domain-specific cognitive functions may change over the course of 
disease, where effects on typical cognitive measures of visuospatial 
performance may only become apparent at more severe degrees of 
cholinergic degeneration and closer to the time of dementia diagnosis. 
A striking finding of our study is that, in contrast to CBF volume, 
hippocampal volume did not show robust associations with cognition 
after controlling for confounding variables that are likely to mediate 
such an association, particularly age and disease severity. Several pre-
vious structural MRI studies had reported hippocampal atrophy in PD 
patients with cognitive impairment and particularly in PDD [12,13]. 
However, studies investigating the implication of the hippocampus in 
cognitive impairments among non-demented PD patients have produced 
mixed results, and a recent meta-analysis of structural MRI findings 
could confirm significant hippocampus atrophy in PDD but not in 
PD-MCI [25]. Our combined assessment of hippocampal and CBF vol-
ume in the same study sample of non-demented PD patients indicates 
that cognitive deficits at this stage more closely relate to CBF atrophy 
than to hippocampal atrophy. Macroscopic hippocampal atrophy as 
Fig. 1. Associations of volumetric and diffusion-based imaging markers with PD-CRS total scores. (A) Residualized cholinergic basal forebrain volume accounted for 
TIV and acquisition site plotted against PD-CRStotal score. (B) Residualized cholinergic basal forebrain mean diffusivity accounted for acquisition site plotted against 
PD-CRStotal score. (C) Residualized hippocampal volume accounted for TIV and acquisition site plotted against PD-CRStotal score. (D) Residualized hippocampal mean 
diffusivity accounted for acquisition site plotted against PD-CRStotal score. For visualization purposes mean diffusivity scores were scaled by a factor of 1000. For 
better comparability between volumetric and diffusion-based imaging markers, all imaging-cognition associations were plotted for the subset of PD patients who had 
both imaging modalities available. 
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measured by volumetric changes on MRI may only occur at a later stage 
of PD-related cognitive decline. 
However, more subtle neuroimaging measures may increase the 
sensitivity to detect early neurodegenerative tissue changes in the hip-
pocampus already at a predementia stage in PD. Thus, a previous 
multimodal MRI/DTI imaging study found that hippocampal diffusivity 
changes correlated with memory performance among non-demented PD 
patients, but no significant associations were observed for hippocampal 
volume [14]. In our DTI substudy we could confirm that hippocampal 
diffusivity measures were more closely associated with cognition in 
non-demented PD compared to volume, although this association 
showed a rather unexpected specificity for verbal fluency instead of 
memory measures. 
Interestingly, in contrast to the findings for the hippocampus, DTI- 
based diffusivity measures of the CBF were not associated with cogni-
tion in our sample. This is partly in contrast to a previous MRI/DTI study 
in de novo PD patients from the PPMI cohort [11], which found both 
CBF volume and MD to be significant predictors of prospective cognitive 
decline. Similarly, another recent DTI study found significant 
cross-sectional correlations between diffusivity changes in CBF ROIs and 
cognitive performance in non-demented PD patients, but CBF volumes 
were not assessed in that study [26]. These different findings could at 
least partly relate to differences in patient characteristics, as the pro-
portion of PD-MCI patients was notably higher (20 out of 52 patients; 
38%) in this previous study compared to our current study sample (16 
out of 73 patients with PD-CRStotal ≤ 81; 22%). However, they may also 
reflect a generally higher variability in DTI-based diffusion measures, 
which are known to be more susceptible to noise compared to standard 
volumetric measures on structural MRI [27]. 
This study has several limitations. First, although the multicentric 
design of the study allowed us to assess CBF-cognition associations in a 
relatively large and clinically diverse sample of PD patients, the 
extracted imaging indices may have been affected by the multicentric 
acquisition of the imaging data, which is particularly a concern for the 
DTI signal measurements [27]. In addition to a generally higher sus-
ceptibility to inter-scanner related variance, DTI signal measurements 
may potentially also be more prone to other signal confounders, such as 
for example contamination by CSF signal that borders the ventral limit 
of the basal forebrain. Thus, besides modality-specific sensitivities for 
distinct neuropathological processes, the observed differences in 
cognition associations between these imaging modalities may also relate 
to technical differences in the MRI- and DTI-based measurements. 
However, it has to be noted that we controlled all our statistical analyses 
for the different acquisition sites, and the multicentric design also 
allowed us to demonstrate the robustness of the CBF-cognition associ-
ations across centers (see center-specific meta-analysis in the supple-
mentary material), which is a key requirement of potential imaging 
markers that are to be used in wider clinical setting. Another limitation 
is the cross-sectional nature of our study. It remains to be determined 
whether the observed cognition-relevant differences in CBF volume 
among PD patients also translate to a higher risk for progression to de-
mentia. Furthermore, the COPPADIS cohort represents a rather selective 
research cohort that may not be reflective of the general PD population, 
and thus our results should be replicated in less preselected cohorts from 
community-based studies. Another important consideration is that the 
employed MRI markers of CBF integrity can only serve as indirect 
markers of cholinergic degeneration. The analyzed CBF region corre-
sponds to the localization of the cholinergic nuclei in the human brain as 
determined by cytoarchitectonic mappings from combined histology 
and post-mortem MRI [20], and imaging-pharmacologic [6] and 
imaging-neurophysiologic [28] studies provide evidence for a link be-
tween CBF integrity on MRI and cholinergic system functioning. How-
ever, one cannot exclude that the imaging indices might also reflect 
change in other neuronal or glial components. Finally, the correlation 
coefficients for the association between CBF volume and cognition are of 
rather moderate effect size, which, however, lies well in the range of 
previous studies assessing associations between regional imaging mea-
sures and cognition in PD [4,10,14]. Associations between neuro-
imaging measures and clinical outcomes can rarely be expected to be 
strictly linear and will generally depend on the functional consequences 
of the neurodegenerative process that is indexed by the macro- and 
microstructural neuroimaging alterations. A recent 
imaging-neuropathology association study found that CBF volume on 
structural MRI correlated with the extent of Lewy body pathology in the 
nucleus basalis of Meynert, but not with semi-quantitative assessments 
of cell loss in this region [29]. This indicates that the neuroimaging 
measures may also pick up relatively subtle tissue changes in response to 
neurodegenerative pathology [30]. 
In conclusion, we demonstrate in a well-characterized multicentric 
sample of PD patients without dementia that cognitive differences in this 
non-demented spectrum are more closely related to structural MRI 
measures of CBF degeneration than hippocampal degeneration. DTI- 
based diffusion measures could increase the sensitivity to detect 
Table 3 
Linear model stats for the association of diffusivity imaging markers with 




Cholinergic Basal Forebrain Hippocampus 





Part. r T value (P 
value) 
P(FDR) 
PD-CRStotal − 0.10 − 0.82 
(0.418) 
0.418 − 0.43 − 3.98 
(<0.001) 
<0.001    








0.958 0.02 0.20 
(0.843) 
0.843       
Working 
memory 
− 0.10 − 0.84 
(0.404) 
0.95 − 0.26 − 2.22 
(0.030) 
0.049    





− 0.08 − 0.63 
(0.528) 
0.95 − 0.26 − 2.27 
(0.026) 
0.049    








0.958 − 0.49 − 4.72 
(<0.001) 
<0.001    





− 0.01 − 0.10 
(0.924) 
0.958 − 0.30 − 2.58 
(0.012) 
0.036    






− 0.24 − 2.01 
(0.048) 
0.216 − 0.18 − 1.53 
(0.131) 
0.147 
− 0.14 − 1.10 
(0.274) 




− 0.27 − 2.37 
(0.021) 
0.186 − 0.25 − 2.18 
(0.033) 
0.049 
− 0.14 − 1.14 
(0.257) 




Naming − 0.02 − 0.20 
(0.846) 
0.958 − 0.21 − 1.80 
(0.077) 
0.099       
Clock copy − 0.09 − 0.77 
(0.445) 
0.95 − 0.32 − 2.85 
(0.006) 
0.026    
− 0.18 − 1.42 
(0.161) 
0.323 
Linear model stats are presented as (partial) r and T value (P value). For each 
cognitive item score, results from single predictor linear regression models 
(controlled for acquisition site) are indicated in the first row, and for significant 
models fully covariate-controlled regression results are indicated in the second 
row. 
Abbreviations: PD-CRS = PD-Cognitive Rating Scale. 
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cognition-relevant tissue changes in the hippocampus, but at least in the 
context of unharmonized multicentric imaging acquisitions appear to be 
inferior to standard volumetric measures for capturing cognition- 
relevant CBF changes. These findings may have important implica-
tions for the development of clinically useful imaging biomarkers aiding 
in the early detection of PD patients at increased risk for cognitive 
decline. 
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